Daiichi Sankyo Company, Limited

Sanford Burnham Prebys Medical Discovery Institute

Masamichi Kishida

Jun Kobayashi

Yoshiyuki Onishi

Tsutomu Nagata

Kengo Noguchi

Anthony B Pinkerton

Yuko Yamamoto

Shojiro Miyazaki

Masanori Izumi

Masaharu Inui

Kaori Soma

Yasunobu Kurosaki

The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof. 

Sulfonamide compounds

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein Rrepresents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R, R, and Reach independently represent a hydrogen atom or a C1 to C3 alkyl group; R, R, R, R, R, and Reach independently represent a hydrogen atom or the like; and Rrepresents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

Cyclopropanecarboxylic acid derivative

Growing community of inventors

Tokyo, Japan

Masamichi Kishida